AbbVie Inc. (ABBV) Stock: Surge as VRAYLAR Data Strengthens Mood Disorder Treatment Case 

TLDR AbbVie shares rise as VRAYLAR data strengthens its mood disorder treatment case. VRAYLAR real-world studies show gains in depression symptoms and daily function. Bipolar I patients recorded better symptoms, functioning, and quality of life. AbbVie expands VRAYLAR evidence with pediatric safety and comparative research. Patient survey results support adjunctive treatment after weak antidepressant response. [...]

The post AbbVie Inc. (ABBV) Stock: Surge as VRAYLAR Data Strengthens Mood Disorder Treatment Case  appeared first on Blockonomi.